Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554984 | 0.90 | HCAR2 (0.57) | HCAR2 | |
| SCHEMBL10312550 | 0.87 | HCAR2 (0.51) | HCAR2SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL4548429 | 0.82 | MAOB (0.46) | HCAR2PSMB5LMNASMN1; SMN2MAPT | |
| SCHEMBL10312560 | 0.78 | CYP2C9 (0.46) | HCAR2PSMB5LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL10312557 | 0.76 | HCAR2 (0.36) | HCAR2PSMB5SMN1; SMN2MAPTNPC1 | |
| SCHEMBL4548475 | 0.75 | HCAR2 (0.64) | HCAR2 | |
| SCHEMBL10312532 | 0.74 | MITF (0.54) | HCAR2LMNAMAPTALDH1A1TSHR | |
| SCHEMBL10312533 | 0.74 | MAPT (0.48) | HCAR2LMNAMAPK1SMN1; SMN2MAPT | |
| SCHEMBL10312563 | 0.73 | TP53 (0.54) | HCAR2LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL10312554 | 0.72 | RAB9A (0.49) | HCAR2SMN1; SMN2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | HCAR2 2/4885PSMB5 2936/4885LMNA 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.